1,980 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Aljian Capital Management LLC

Aljian Capital Management LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,980 shares of the life sciences company’s stock, valued at approximately $258,000.

Other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc increased its holdings in Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 246 shares in the last quarter. Industrial Alliance Investment Management Inc. purchased a new position in shares of Illumina during the second quarter valued at approximately $34,000. Massmutual Trust Co. FSB ADV grew its holdings in Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after buying an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in Illumina in the 2nd quarter valued at $61,000. Finally, Mizuho Securities Co. Ltd. bought a new position in Illumina during the 2nd quarter valued at $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Down 5.1 %

Shares of ILMN stock opened at $135.05 on Monday. The stock has a fifty day simple moving average of $139.66 and a two-hundred day simple moving average of $124.31. Illumina, Inc. has a 52-week low of $92.69 and a 52-week high of $156.66. The firm has a market capitalization of $21.42 billion, a PE ratio of -13.56 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter last year, the company earned $0.33 EPS. The firm’s quarterly revenue was down 3.5% on a year-over-year basis. On average, analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. TD Cowen boosted their price target on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Morgan Stanley restated an “equal weight” rating and issued a $156.00 target price on shares of Illumina in a research note on Tuesday, November 12th. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research report on Tuesday, November 5th. Royal Bank of Canada lifted their price target on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Finally, Piper Sandler reduced their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $164.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.